Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 10/20 | 0.43 |
| ▸ | PPARG | P37231 | 9/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | SDCBP | O00560 | 1/20 | 0.39 |
| ▸ | SDC2 | P34741 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523786 | 0.84 | MAPT (0.42) | MAPTPPARAPPARGAPPCTSS | |
| SCHEMBL2573117 | 0.81 | CTSK (0.45) | PPARAPPARGAPPCTSSCTSK | |
| SCHEMBL3379781 | 0.81 | CTSK (0.51) | MAPTPPARAPPARGAPPCTSS | |
| SCHEMBL4116995 | 0.81 | CTSK (0.51) | MAPTPPARAPPARGAPPCTSS | |
| SCHEMBL844407 | 0.81 | CTSK (0.51) | MAPTPPARAPPARGAPPCTSS | |
| SCHEMBL3414715 | 0.81 | CTSK (0.51) | MAPTPPARAPPARGAPPCTSS | |
| SCHEMBL14250689 | 0.81 | CTSK (0.51) | MAPTPPARAPPARGAPPCTSS | |
| SCHEMBL4683822 | 0.80 | CTSK (0.46) | APPCTSSCTSK | |
| SCHEMBL22303774 | 0.80 | CTSK (0.41) | PPARAPPARGCA2APPCTSS | |
| SCHEMBL6107389 | 0.80 | CTSK (0.41) | PPARAPPARGCA2APPCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309207-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2016-04-12 | — | — | US | disclosed |
| US-8722655-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINC1 | MAPT 3434/4885PPARA 2356/4885PPARG 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.